Jazz Pharmaceuticals (JAZZ) Stock News

Jazz Pharmaceuticals (Nasdaq:JAZZ) reported second interim overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Ziihera® (zanidatamab-hrii) plus chemotherapy showed statistically significant, clinically meaningful OS improvement versus trastuzumab plus chemotherapy, with an improved OS hazard ratio versus the first interim analysis.

According to Jazz, longer follow up also improved the OS hazard ratio for Ziihera + Tevimbra® (tislelizumab) + chemotherapy, reinforcing this regimen as the company’s proposed new standard of care in the U.S. The FDA approved Ziihera regimens on August 25, 2026 for first-line HER2+ GEA. Ziihera carries Boxed Warnings for severe diarrhea and embryo-fetal toxicity, and detailed safety data show high rates of diarrhea, left ventricular dysfunction, infusion-related reactions and serious adverse events.

Jazz Pharmaceuticals (Nasdaq: JAZZ) priced an upsized private offering of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032, issued by wholly owned subsidiary Jazz Investments I Limited to qualified institutional buyers under Rule 144A. Initial purchasers have a 13-day option to buy up to an additional $150 million of notes. The notes mature on September 15, 2032, pay semiannual interest at 1.875%, and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 (exchange price about $355.24, a ~42.5% premium to the August 26, 2026 close). The notes are senior unsecured, fully and unconditionally guaranteed by Jazz Pharmaceuticals, with various tax, optional and cleanup redemption features and fundamental change repurchase rights.

Net proceeds are estimated at $1,079.0 million (or $1,226.4 million if the option is fully exercised), to be used for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase about $225.0 million of its ordinary shares at $249.29 per share, paid from existing cash under its July 2024 share repurchase program.

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that its wholly owned subsidiary, Jazz Investments I Limited, intends to privately offer $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $150.0 million of notes. The notes will be senior unsecured obligations, fully and unconditionally guaranteed by Jazz, accrue interest semiannually, and be exchangeable into cash, Jazz ordinary shares, or both, subject to conditions. According to Jazz, net proceeds are expected to be used for general corporate purposes.

Jazz also expects to conduct concurrent ordinary share repurchases of up to $225.0 million from note purchasers in privately negotiated transactions, funded with existing cash and under its July 2024 repurchase program, which will reduce the remaining authorization.

Jazz Pharmaceuticals (Nasdaq:JAZZ) announced U.S. FDA approval of two Ziihera (zanidatamab-hrii) regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA). One regimen combines Ziihera with Tevimbra (tislelizumab) plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+); the other combines Ziihera with chemotherapy alone (HER2+ IHC 3+).

According to Jazz, Phase 3 HERIZON-GEA-01 data showed median progression-free survival of 12.4 months versus 8.1 months and median overall survival of 26.4 versus 19.2 months versus trastuzumab plus chemotherapy, with risk reductions of 35% for progression or death and 28% for death. Ziihera regimens carry boxed warnings for severe diarrhea and embryo-fetal toxicity, and additional risks including left ventricular dysfunction and infusion-related reactions. Jazz will host an investor webcast on August 25, 2026, at 4:30 p.m. ET to discuss the approval and the zanidatamab program.

Jazz Pharmaceuticals (Nasdaq: JAZZ) agreed to acquire privately held Actio Biosciences for an $820 million upfront payment plus up to $500 million in approval and sales milestones, adding ABS-1230, a clinical-stage, potential first-in-class KCNT1 ion channel inhibitor for KCNT1+ epilepsy, an ultra-rare disease with no FDA-approved therapies.

The ongoing Phase 1b/2a KYRON trial of ABS-1230 is intended as the U.S. registrational study and the drug has FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations, and acceptance into the FDA’s Rare Disease Evidence Principles (RDEP) program. At closing, Actio will spin out a new rare-neurology company retaining assets such as ABS-0871 for Charcot-Marie-Tooth type 2C, funded by existing investors, in which Jazz will receive a minority stake. The all-cash transaction, unanimously approved by both boards, is expected to close by the fourth quarter of 2026, financed with cash on hand and existing facilities.

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported record 2Q26 total revenues of $1.21 billion, up 16% year over year, with GAAP EPS of $2.78 and non-GAAP adjusted EPS of $5.71. Xywav sales grew 13% to $471 million, Epidiolex/Epidyolex 16% to $292 million, and Zepzelca 42% to $106 million, while Modeyso contributed $48 million and Ziihera $15 million in 2Q26.

According to Jazz Pharmaceuticals, 1H26 cash from operations reached $824 million, with cash and investments of $2.2 billion and long‑term debt of $4.4 billion after repaying $1.0 billion of exchangeable notes. The company raised 2026 revenue guidance to $4.60–$4.75 billion and highlighted upcoming FDA action for Ziihera in HER2+ 1L GEA on August 25, 2026, plus Breakthrough Therapy designation in HER2‑positive colorectal cancer.

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to review results and provide a business and financial update.

Interested participants can register via the Investors section of the Jazz Pharmaceuticals website and are encouraged to do so at least 15 minutes before the webcast. A replay will be available on the same site. Jazz describes itself as a global biopharma company focused on medicines for rare diseases, epilepsies, cancers and sleep disorders.

AbCellera (Nasdaq: ABCL) and Jazz Pharmaceuticals announced a preclinical collaboration, option and license agreement to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.

AbCellera receives $56 million upfront, up to $28 million for a third program, and may earn up to $792 million per program in potential option, development, regulatory and commercial milestone payments, plus tiered royalties on net sales.

Jazz Pharmaceuticals (Nasdaq:JAZZ) presented 11 late-breaking data sets at SLEEP 2026 on Xywav in narcolepsy and idiopathic hypersomnia. Findings highlight individualized dosing optimization, real-world feasibility in over 13,000 patients, and cardiometabolic markers potentially affected by Xywav’s low-sodium formulation, including blood pressure, lipids, and sodium-related symptoms.